Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH PUBLISHING
GLOBETECH PUBLISHING
PZ HTL SA

Chronic Inflammation Maintained by the Immunosuppressive Action of TNF-alpha

By BiotechDaily International staff writers
Posted on 18 Apr 2013
Researchers studying how the immune system deals with chronic inflammation have found that the cytokine tumor necrosis factor-alpha (TNF-alpha) exhibits a dual function during chronic inflammation that results in the formation of an immunosuppressive environment that supports the continuation of the inflammatory condition.

TNF is primarily produced as a 212-amino acid-long type II transmembrane protein arranged in stable homotrimers. From this membrane-integrated form, the soluble homotrimeric cytokine (sTNF) is released via proteolytic cleavage by the metalloprotease TNF-alpha converting enzyme (TACE). The soluble 51-kDa trimeric sTNF tends to dissociate at concentrations below the nanomolar range, thereby losing its bioactivity. The secreted form of human TNF-alpha takes on a triangular pyramid shape, and weighs around 17 kDa. Both the secreted and the membrane bound forms are biologically active and have both overlapping and distinct biology activities. TNF-alpha is particularly important as a part of the body's inflammatory response and in normal circumstances (where it is released locally in low levels) helps the immune system defeat pathogens. However, when it is systemically released in the blood and in high levels, it can cause severe and life-threatening symptoms, including shock and multiple organ failure.

Investigators at the Hebrew University of Jerusalem (Israel) had shown previously that in the course of chronic inflammation, myeloid derived suppressor cells (MDSCs)—unique immune system cells with suppressive features—were generated in the bone marrow and migrated into various organs and the blood, imposing a general immune suppression. In the current work, they linked the generation of MDSCs to the activity of TNF-alpha.

Results reported in the March 21, 2013, issue of the journal Immunity revealed that in a mouse model TNF-alpha exhibited a dual function during chronic inflammation. It blocked differentiation of immature MDSCs primarily via the S100A8 and S100A9 inflammatory proteins and their corresponding receptor (RAGE) and augmented MDSC suppressive activity. These functions led to in vivo T- and NK-cell dysfunction accompanied by T-cell antigen receptor zeta-chain downregulation. This activity impaired the animals' immune responses as reflected by their inability to respond against invading pathogens or against developing tumors.

However, administration of the drug etanercept (a TNF-alpha antagonist) during early chronic inflammatory stages reduced MDSCs’ suppressive activity and enhanced their maturation into dendritic cells and macrophages, resulting in the restoration of in vivo immune functions and recovery of zeta chain expression.

These results provide new insights into the relationship between TNF-alpha and the development of immune suppression during chronic inflammation. They may aid in the generation of better therapeutic strategies against various pathologies involving elevated TNF-alpha and MDSC levels.

Related Links:
Hebrew University of Jerusalem


Channels

Drug Discovery

view channel
Image: Chitosan is derived from the shells of shrimp and other sea crustaceans, including Alaskan pink shrimp, pictured here (Photo courtesy of NOAA - [US] National Oceanic and Atmospheric Administration).

Chitosan Treatment Clears the Way for Antibiotics to Eliminate Recurrent Urinary Tract Infections

Recurrent urinary tract infection was successfully resolved in a mouse model by treatment with the exfoliant chitosan followed by a round of antibiotics. Bacterial urinary tract infection (UTI), most... Read more

Biochemistry

view channel

Mitochondrial Cause of Aging Can Be Reversed

Researchers have found a cause of aging in lab animals that can be reversed, possibly providing an avenue for new treatments for age-related diseases including type 2 diabetes, cancer, muscle wasting, and inflammatory diseases. The researchers plan to begin human trials late 2014. The study, which was published December... Read more

Therapeutics

view channel

Cytokine Identified That Causes Mucositis in Cancer Therapy Patients

The action of the cytokine interleukin 1-beta (IL-1beta) has been found to underlie the onset of mucositis, a common, severe side effect of chemotherapy and irradiation of cancer patients. Mucositis occurs as a result of cell death in reaction to chemo- or radiotherapy. The mucosal lining of the mouth becomes thin, may... Read more

Business

view channel

Analytical Sciences Trade Fair Declared a Rousing Success

Organizers of this year's 24th "analytica" biosciences trade fair have reported significant increases in both the number of visitors and exhibitors compared to the 2012 event. The analytica trade fair for laboratory technology, analysis, and biotechnology has been held at the Munich (Germany) Trade Fair Center every... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.